New cell therapy CPTX2309 enters human testing for autoimmune diseases
NCT ID NCT06917742
First seen Apr 01, 2026 · Last updated May 23, 2026 · Updated 8 times
Summary
This early-stage study tests the safety of a new drug called CPTX2309 in healthy people and those with moderate to severe rheumatoid arthritis or lupus. Researchers will give the drug through a vein and watch for side effects, changes in lab tests, and how the body responds. The goal is to see if it is safe enough to study further.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Nucleus Network Brisbane
RECRUITINGHerston, Queensland, 4006, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.